By Dr. Gary Walsh (auth.), Gary Walsh, Brendan Murphy (eds.)
Biopharmaceuticals, an commercial Perspective offers a special and up to date perception into the biopharmaceutical undefined. principally written by way of business authors, its scope is multidisciplinary. a number of chapters evaluation the construction and clinical functions of particular biopharmaceuticals. different chapters element extra appropriate matters, together with the stabilisation of biopharmaceutical items, ecu biopharmaceutical regulatory affairs and biopharmaceutical patent legislation. a sequence of 4 chapters reports vital validation matters as utilized to biopharmaceutical production. extra matters thought of contain biopharmaceutical details expertise in addition to viral and non-viral gene treatment.
The publication is of specific relevance to scientists and allied execs already hired within the biopharmaceutical undefined, or to these looking employment inside of this undefined. Its scope additionally renders it an incredible reference resource for college students project complex undergraduate or postgraduate classes in biotechnology, pharmaceutical technological know-how, biochemistry or medicine.
Read Online or Download Biopharmaceuticals, an Industrial Perspective PDF
Similar industrial books
Industrial Metrology: Surfaces and Roundness
The topic of this booklet is floor metrology, specifically significant elements: floor texture and roundness. It has taken decades for production engineers and architects to grasp the usefulness of those positive factors in caliber of conformance and caliber of layout. regrettably this knowledge has come at a time while engineers versed within the use and specification of surfaces are at a top rate.
Advances in Solar Energy Technology: Volume 2: Industrial Applications of Solar Energy
The aim of penning this 3 quantity 'Advances in solar power expertise' is to supply all of the suitable most up-to-date details to be had within the box of solar power (Applied in addition to Theoretical) to function the easiest resource fabric at one position. makes an attempt are made to debate subject matters extensive to aid either the scholars (i.
Industrial Enzymes: Structure, Function and Applications
Man's use of enzymes dates again to the earliest occasions of civilization. vital human actions corresponding to the construction of specific sorts of meals and drinks, and the tanning of hides and skins to supply leather-based for clothes, serendipitously took benefit of enzyme actions. vital advances in our realizing of the character of enzymes and their motion have been made within the past due nineteenth and early twentieth centuries, seeding the explosive growth from the Fifties and 60s onward to the current billion greenback enzyme undefined.
Extra resources for Biopharmaceuticals, an Industrial Perspective
Example text
Nuclease therapeutics in the clinic. Biorrechnology, 11,580582. 3l. Conway, S. and Watson, A (1997). Nebulized broncodialators, corticosteroids and rh DNase in adult patients with cystic fibrosis. Thorax, 52(2), 564-568. 32. Johnson (1983). Human insulin from recombinant DNA technology. Science, 219, 632-637. 33. Lippe, B. and Nakamoto, 1. (1993). Conventional and non-conventional uses of growth hormone. Recent Prog. Horm. , 48, 179-235. 34. Neely, E. (1994). Use and abuse of human growth hormone.
JWle), 8085. 66. Hodgson, C. (1995). The vector void in gene therapy. Bioffechnology, 13, 222-225. 67. Askari, F. (1996). Molecular medicine: antisense oligonucleotide therapy. N. Eng. 1. , 334(5), 316-318. 68. Putnam, D. (1996). Antisense strategies and therapeutic applications. Am. 1. Health Syst. , 53, 151-160. Chapter 2 Abciximab: The First Platelet Glycoprotein IIblIlIa Receptor Antagonist Robert E. Jordan, Marian T. Nakada, Harlan F. , Malvern, Pennsylvania, USA Key words: abciximab, GP IIblIIla, platelets, ReoPro, monoclonal antibody, antithrombotic therapy.
Weisman At 24 hours following the bolus dose, the level of GP llblilla receptor blockade had fallen to 50% to 60% and platelet aggregation was inhibited by only 60%. Since it is likely to take more than 8 hours for an injured atherosclerotic blood vessel to tuldergo passivation (24), that is, to become nonthrombogenic and nonplatelet-reactive, it was suspected that the duration of platelet inhibition achieved with a single bolus dose might not be therapeutically adequate. A bolus dose followed by a continuous infusion proved to be more effective in producing sustained platelet inhibition.